Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J P Pinto

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Thrombolysis|February 15, 2011
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitorPancras C Wong, Donald J P Pinto, Donglu Zhang
Expert Opinion on Therapeutic Patents|June 5, 2012
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent reviewDonald J P Pinto, Jennifer X Qiao, Robert M Knabb
Cardiovascular Drug Reviews|August 15, 2002
Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agentPancras C Wong, Donald J P Pinto, Robert M Knabb
Journal of Enzyme Inhibition and Medicinal Chemistry|December 22, 2010
Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasmaJoseph M Luettgen, Robert M Knabb, Kan He, et al.
Journal of Medicinal Chemistry|May 19, 2018
Factor XIa Inhibitors as New AnticoagulantsMimi L Quan, Donald J P Pinto, Joanne M Smallheer, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbitsPancras C Wong, Earl J Crain, Carol A Watson, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2014
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moietiesMichael J Orwat, Jennifer X Qiao, Kan He, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 5, 2011
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitorKan He, Joseph M Luettgen, Donglu Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2010
Phenyltriazolinones as potent factor Xa inhibitorsMimi L Quan, Donald J P Pinto, Karen A Rossi, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Thrombolysis|February 15, 2011
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitorPancras C Wong, Donald J P Pinto, Donglu Zhang
Expert Opinion on Therapeutic Patents|June 5, 2012
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent reviewDonald J P Pinto, Jennifer X Qiao, Robert M Knabb
Cardiovascular Drug Reviews|August 15, 2002
Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agentPancras C Wong, Donald J P Pinto, Robert M Knabb
Journal of Enzyme Inhibition and Medicinal Chemistry|December 22, 2010
Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasmaJoseph M Luettgen, Robert M Knabb, Kan He, et al.
Journal of Medicinal Chemistry|May 19, 2018
Factor XIa Inhibitors as New AnticoagulantsMimi L Quan, Donald J P Pinto, Joanne M Smallheer, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbitsPancras C Wong, Earl J Crain, Carol A Watson, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2014
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moietiesMichael J Orwat, Jennifer X Qiao, Kan He, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 5, 2011
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitorKan He, Joseph M Luettgen, Donglu Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2010
Phenyltriazolinones as potent factor Xa inhibitorsMimi L Quan, Donald J P Pinto, Karen A Rossi, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitorsJeffrey G Varnes, Dean A Wacker, Donald J P Pinto, et al.
Pageof 3